Qiagen (QGEN, Financial) has entered into a strategic collaboration with Tracer Biotechnologies to develop and bring to market assays for minimal residual disease (MRD) in solid tumors using the QIAcuity digital PCR platform. The partnership's objective is to provide oncologists with tools for precise cancer recurrence monitoring and to aid in personalizing treatment plans, all through the use of minimally invasive blood tests. This initiative seeks to offer highly sensitive and cost-effective MRD testing solutions that can be implemented more widely in medical settings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Qiagen NV (QGEN, Financial) is $49.71 with a high estimate of $55.00 and a low estimate of $45.00. The average target implies an upside of 9.10% from the current price of $45.56. More detailed estimate data can be found on the Qiagen NV (QGEN) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Qiagen NV's (QGEN, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Qiagen NV (QGEN, Financial) in one year is $48.96, suggesting a upside of 7.46% from the current price of $45.56. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Qiagen NV (QGEN) Summary page.
